Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Schroder Adveq

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 31
Average round size
The average size of a deal this fund participated in
Portfolio companies 20
Rounds per year 1.24
Lead investments 1
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 4
Key employees 13
Stages of investment
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Life Science

Schroder Adveq appeared to be the VC, which was created in 1997. The company was established in Europe in Switzerland. The leading representative office of defined VC is situated in the Zu00fcrich.

Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular fund investment industries, there are Pharmaceutical, Health Diagnostics. The fund has exact preference in some founders of portfolio startups. For fund there is a match between the location of its establishment and the land of its numerous investments - Switzerland. Among the various public portfolio startups of the fund, we may underline Decibel Therapeutics, Nohla Therapeutics, Memo Therapeutics

Besides them, we counted 13 critical employees of this fund in our database.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Schroder Adveq, startups are often financed by Third Rock Ventures, Venture Kick, Lightspeed China Partners. The meaningful sponsors for the fund in investment in the same round are VI Partners AG, Third Rock Ventures, Redalpine Venture Partners. In the next rounds fund is usually obtained by Vivo Capital, VI Partners AG, Third Rock Ventures.

The fund is generally included in 2-6 deals every year. The real fund results show that this VC is 9 percentage points less often commits exit comparing to other companies. The top activity for fund was in 2018. The increased amount of exits for fund were in 2019. Opposing the other organizations, this Schroder Adveq works on 18 percentage points less the average amount of lead investments. The common things for fund are deals in the range of 10 - 50 millions dollars.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Schroder Adveq:
Typical Co-investors
Schroder Adveq is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Schroder Adveq:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from Switzerland
Funds with similar focus located in Switzerland:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

ImmunOs Therapeutics

Drug Discovery
Health Care
$77M07 Jun 2022 Zurich, Switzerland

HAYA Therapeutics

Health Care
$5M09 Feb 2022 Lausanne, Vaud, Switzerland

LEAP India

Management Consulting
Supply Chain Management
$34M04 Aug 2021 Mumbai, Maharashtra, India

Alentis Therapeutics

$65M15 Jun 2021 Basel, Basel-City, Switzerland


Artificial Intelligence
Cyber Security
Machine Learning
Professional Services
$65M25 May 2021 London, England, United Kingdom

HAYA Therapeutics

Health Care
$19M20 May 2021 Lausanne, Vaud, Switzerland


Packaging Services
$51M26 Apr 2021 Mumbai, Maharashtra, India

Synendos Therapeutics

Health Care
$21M12 Nov 2020 Basel-Country, Switzerland

Memo Therapeutics

$15M06 Nov 2020 Zurich, Zurich, Switzerland
HAYA Therapeutics Completes CHF 18 Million Seed Financing To Advance Anti-fibrotic Therapies Targeting Long Non-coding RNAs

– HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), announced the successful closing of its CHF 18 million seed round.
– The financing was led by Broadview Ventures, with participation from Apollo Health Ventures, BERNINA BioInvest, 4See Ventures, Schroder Adveq and Viva BioInnovator.
– Founded and led by a team of experts in lncRNA biology and fibrotic disease, HAYA will use the funds from the financing to advance the discovery and development of innovative organ and cell-selective therapeutics that target lncRNAs to treat and potentially reverse fibrosis and other serious medical conditions related to aging.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Schroder Adveq?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: